THE Pharmaceutical Benefits
Advisory Committee has
recommended that the Australian
Government fund Alexion
Pharmaceuticals’ drug Soliris
(eculizumab) for the treatment of
Paroxysmal Nocturnal
Haemoglobinuria (a rare lifethreatening
blood disorder that
causes premature red blood cell
death) through the Life Saving
Drugs Program.
Despite the recommendation, in
order for Soliris to receive the
funding under the scheme, funding
arrangements need to be
negotiated with Alexion
Pharmaceuticals.
In addition, an expert Disease
Advisory Committee is being
established to develop eligibility
and continuation criteria for
patients to receive Soliris
treatment, and treatment
guidelines.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Sep 10
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.